B · Normal
[Pfizer Eliquis sales increased by 25% in the third quarter and Padcev increased by 55%] On November 3, Pfizer’s third quarter Eliquis global sales increased by 25% year-on-year, an increase of US$513 million; Padcev sales increased by 55%, an increase of US$255 million; the Vyndaqel series increased by 12%, Nurtec increased by 33%, and Lorbrena increased by 43%. During the same period, sales of Paxlovid fell 63% and Comirnaty fell 29%.
Comments